Article Text

other Versions

Download PDFPDF
Elucidating minimal important difference in childhood interstitial lung diseases
  1. Silvija-Pera Jerkic,
  2. Johannes Schulze
  1. Department for Children and Adolescents, Division of Allergy, Pneumology, and Cystic Fibrosis, Goethe University Frankfurt, Frankfurt am Main, Germany
  1. Correspondence to Dr Silvija-Pera Jerkic, Department for Children and Adolescents, Division of Allergy, Pneumology, and Cystic Fibrosis, Goethe University Frankfurt Faculty 16 Medicine, Frankfurt am Main 60590, Germany; Pera-Silvija.Jerkic{at}kgu.de

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Rare paediatric lung diseases have been a challenge over years for paediatric pulmonologists.

There has been growing attention to rare lung diseases in paediatrics in recent years. Especially, childhood interstitial lung disease (chILD) became an area of special interest since comprehensive classification systems1 and clinical network2 have been steadily developed.

chILD is an umbrella term representing a highly heterogenous group of rare diseases comprising more than 200 different lung conditions.2 The incidence in Europe is 0.5–1 case in 100 000.3 In the UK and Ireland, the prevalence is estimated as 0.36 cases per 100 000 children.4 The prognosis varies from a mild, self-limiting disease to a rapidly progressive, fulminant course and individual diagnosis are often associated with substantial morbidity and mortality.2

As most centres only see few cases per year, there is limited knowledge about the onset, severity and the course of each of …

View Full Text

Footnotes

  • Contributors S-PJ wrote the article, JS added paragraphs and reviewed the article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles

  • Paediatric lung disease
    Matthias Griese Nicolaus Schwerk Julia Carlens Martin Wetzke Nagehan Emiralioğlu Nural Kiper Joanna Lange Katarzyna Krenke chILD collaborators Elias Seidl